A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase II, Open-labeled, Randomised, Parallel, Non-comparative, Two-arms,
Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With
Apatinib (VEGFR2 inhibitor) in Subjects with Advanced Triple Negative Breast Cancer. Subjects
with advanced Triple Negative Breast Cancer will be recruited. Patients will be randomised to
two treatment arms of this study. One arm is SHR-1210 combination with apatinib daily dosing,
and the other arm is SHR-1210 combination with apatinib intermittent dosing; each arm will
enrolle10-29 subjects (Simons two stage design).
This study aims to evaluate the efficacy and safety of SHR-1210 combination with apatinib in
the treatment of advanced TNBC.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University